Adenovirus (AAV rh74)-based gene therapy prices and purchasing channels

Delandistrogene moxeparvovec-rokl, based on adenovirus (AAV rh74) gene vector, is a gene therapy for the treatment of Duchenne Muscular Dystrophy (DMD). Because it adopts a one-time administration, long-acting treatment model and incorporates advanced genetic engineering technology, its pricing is also relatively high. According to public information, the drug is priced at approximately US$3.3 million per treatment in the United States, making it one of the most expensive drugs in the world. This high price covers the costs of complex links such as gene vector manufacturing, purification, storage, transportation and precise drug delivery, and also reflects the contradiction between technical barriers and market size in the field of rare disease treatment.

For patients, the main channels for purchasing delandistrogene moxeparvovec-rokl are concentrated in countries such as the United States that have approved the drug for marketing. At present, mainland China has not approved the marketing of this therapy. Therefore, if patients need to use it, they generally need to apply for treatment through formal overseas medical referral platforms, cross-border pharmacies, or third-party international medical institutions. Some patients may also choose to go to the United States for evaluation and treatment, but they need to meet the indication requirements for this therapy, including gene mutation type, age (currently only 4 to 5 years old), previous treatment history, and overall physical condition.

Before purchasing and using this drug, patients must undergo rigorous genetic testing and comprehensive medical evaluation to determine whether they meet the medication standards. In addition, delandistrogene moxeparvovec-rokl, as a viral vector gene therapy, has extremely high requirements on the administration environment, and generally needs to be completed in a medical center with high-level biosafety and treatment capabilities. Long-term monitoring of important indicators such as liver function and immune response is also required before and after administration.

Although it is currently not possible to purchase this drug directly in China, some overseas pharmaceutical companies, charitable organizations or patient assistance programs may provide certain support or exemptions for families with financial difficulties. It is recommended that families interested in treatment contact professional doctors or international medical service platforms as soon as possible to obtain personalized treatment suggestions and cost assessments, and prepare in advance visas, language translation, medical materials and other matters related to cross-border medical treatment.

References:

https://www.fda.gov/drugs/drug-approvals-and-databases/delandistrogene-moxeparvovec-rokl